Matrix Laboratories says gets WHO approval for HIV durg
MUMBAI (Reuters) - Matrix Laboratories Ltd said it got approval from the World Health Organisation (WHO) for generic version of a drug to treat the human immuno-deficiency virus (HIV).
The WHO approval enables Matrix to market Lopinavir or Ritonavir tablets in dosages of 200 mg or 50 mg in most countries outside the United States and Europe, the company said in a statement on Thursday.
The tablets are the generic version of Abott Laboratories' Kaltera tablets, it added.
© Thomson Reuters 2010 All rights reserved
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
Greek crisis sets euro zone enlargement back
The Greek debt crisis has dealt a setback to prospects of enlarging the euro zone by highlighting the difficulties of managing the single currency area. Full Article
India
US
UK
